A fixed rate i.v. insulin infusion (FRIII) of short-acting soluble insulin is recommended for the management of certain diabetes-related emergencies including DKA, SGLT-2 inhibitor-induced euglycaemic ketoacidosis, and HHS. This evidence concerns the gene SLC5A2 and diabetes mellitus.